Johnson & Johnson (JNJ)

Executive Summary

Johnson & Johnson (JNJ) is a diversified healthcare leader operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Following the 2023 spin-off of its consumer health business into Kenvue, JNJ now focuses on high-growth areas such as oncology, immunology, and cardiovascular therapies. The company boasts a robust pipeline with over 700 drug candidates, including key assets like Carvykti in multiple myeloma and Tremfya in immunology. Financially, JNJ maintains strong cash flows and a AAA credit rating, enabling continued investment in R&D and strategic acquisitions. However, the company faces ongoing legal challenges related to talc-based products, which have led to significant litigation costs and uncertainty. Despite these headwinds, JNJ's diversified business model and pipeline depth provide a resilient foundation for long-term growth, with the potential for catalysts from new product launches and label expansions. In the near term, JNJ's growth is driven by its Innovative Medicine segment, particularly the launch of new drugs and label expansions for existing blockbusters. The company's MedTech segment is also benefiting from the recovery in elective procedures and innovation in surgical robotics, wound closure, and orthopedics. JNJ's strong balance sheet supports a consistent dividend and share repurchases, appealing to income-oriented investors. While talc litigation remains a overhang, the company is actively working to resolve claims through bankruptcy and settlements. Overall, JNJ is well-positioned to deliver steady performance, with upside potential from pipeline advancements and strategic portfolio optimization.

Upcoming Catalysts (preview)

• Q4 2026Carvykti label expansion for earlier-line multiple myeloma80% success
• TBDTalc litigation resolution (settlement or court ruling)50% success